Key result
NOACs reduce stroke or systemic embolism ~15% vs warfarin in atrial fibrillation.
Why the study?
Do NOACs reduce stroke and systemic embolism in patients with nonvalvular atrial fibrillation?
Do NOACs reduce stroke and systemic embolism in patients with nonvalvular atrial fibrillation?
NOACs are an effective and safer alternative to warfarin for stroke prevention in nonvalvular atrial fibrillation, offering reduced bleeding risk and greater convenience without routine monitoring.
Answers are grounded in this paper and cite their sources.
May support preferring NOACs in AF; hypothesis-generating and requires randomized confirmation before practice change.
Atrial fibrillation is a heart arrhythmia associated with increased risk for ischemic stroke. Vitamin K antagonists were developed to decrease a patient's clotting risk; however, these medications require therapeutic monitoring and have several drug interactions. Novel oral anticoagulants (NOACs) were developed as an alternative to vitamin K antagonists and several studies have evaluated the ability of NOAC to decrease clotting as well as the risk of major bleeding in comparison to vitamin K antagonists, such as warfarin. This study has found that NOACs are as effective as warfarin in reducing stroke and systemic embolism through anticoagulation. Notably, NOACs have a decreased risk of significant bleeding and other secondary adverse events.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2017) conducted a review in Nonvalvular Atrial Fibrillation. Novel oral anticoagulants (NOACs) vs. Warfarin was evaluated on Stroke or systemic embolism (OR 0.85, 95% CI 0.75-0.98). Novel oral anticoagulants demonstrated a reduction in stroke or systemic embolism compared to warfarin in patients with atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: